دورية أكاديمية
Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer
| العنوان: | Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer |
|---|---|
| المؤلفون: | Spratt, Daniel E., George, Daniel J., Shore, Neal D., Cookson, Michael S., Saltzstein, Daniel R., Tutrone, Ronald, Bossi, Alberto, Brown, Bruce A., Lu, Sophia, Fallick, Mark, Hanson, Sarah, Tombal, Bertrand F. |
| المصدر: | JAMA Oncology ; ISSN 2374-2437 |
| بيانات النشر: | American Medical Association (AMA) |
| سنة النشر: | 2024 |
| الوصف: | Importance Combination androgen deprivation therapy (ADT) with radiotherapy is commonly used for patients with localized and advanced prostate cancer. Objective To assess the efficacy and safety of the oral gonadotropin-releasing hormone antagonist relugolix with radiotherapy for treating prostate cancer. Design, Setting, and Participants This multicenter post hoc analysis of patients with localized and advanced prostate cancer receiving radiotherapy in 2 randomized clinical trials (a phase 2 trial of relugolix vs degarelix, and a subset of the phase 3 HERO trial of relugolix vs leuprolide acetate) included men who were receiving radiotherapy and short-term (24 weeks) ADT (n = 103) from 2014 to 2015 and men receiving radiotherapy and longer-term (48 weeks) ADT (n = 157) from 2017 to 2019. The data were analyzed in November 2022. Interventions Patients receiving short-term ADT received relugolix, 120 mg, orally once daily (320-mg loading dose) or degarelix, 80 mg, 4-week depot (240-mg loading dose) for 24 weeks with 12 weeks of follow-up. Patients receiving longer-term ADT received relugolix, 120 mg, orally once daily (360-mg loading dose) or leuprolide acetate injections every 12 weeks for 48 weeks, with up to 90 days of follow-up. Main Outcomes and Measures Castration rate (testosterone level <50 ng/dL [to convert to nmol/L, multiply by 0.0347) at all scheduled visits between weeks 5 and 25 for patients receiving short-term ADT and weeks 5 and 49 for patients receiving longer-term ADT. Results Of 260 patients (38 Asian [14.6%], 23 Black or African American [8.8%], 21 Hispanic [8.1%], and 188 White [72.3%] individuals), 164 (63.1%) received relugolix. Relugolix achieved castration rates of 95% (95% CI, 87.1%-99.0%) and 97% (95% CI, 90.6%-99.0%) among patients receiving short-term and longer-term ADT, respectively. Twelve weeks post–short-term relugolix, 34 (52%) achieved testosterone levels to baseline or more than 280 ng/dL. Ninety days post longer-term ADT, mean (SD) testosterone levels were 310.5 ... |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1001/jamaoncol.2023.7279 |
| الإتاحة: | https://doi.org/10.1001/jamaoncol.2023.7279Test https://jamanetwork.com/journals/jamaoncology/articlepdf/2815669/jamaoncology_spratt_2024_oi_230094_1708543936.03422.pdfTest |
| رقم الانضمام: | edsbas.52354909 |
| قاعدة البيانات: | BASE |
| DOI: | 10.1001/jamaoncol.2023.7279 |
|---|